136 related articles for article (PubMed ID: 35981433)
1. Implantation of two generations of Bonebridge after mastoid obliteration with bioactive glass S53P4.
Skarzynski PH; Krol B; Skarzynski H; Cywka KB
Am J Otolaryngol; 2022; 43(5):103601. PubMed ID: 35981433
[TBL] [Abstract][Full Text] [Related]
2. Implantation of the Bonebridge BCI 602 after Mastoid Obliteration with S53P4 Bioactive Glass: A Safe Method of Treating Difficult Anatomical Conditions-Preliminary Results.
Król B; Cywka KB; Skarżyńska MB; Skarżyński PH
Life (Basel); 2021 Apr; 11(5):. PubMed ID: 33921929
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Bonebridge BCI 602 active bone conductive implant in adults: efficacy and stability of audiological, surgical, and functional outcomes.
Cywka KB; Skarzynski PH; Krol B; Hatzopoulos S; Skarzynski H
Eur Arch Otorhinolaryngol; 2022 Jul; 279(7):3525-3534. PubMed ID: 35182185
[TBL] [Abstract][Full Text] [Related]
4. Mastoid obliteration with S53P4 bioactive glass after canal wall down mastoidectomy: Preliminary results.
Król B; Cywka KB; Skarżyńska MB; Skarżyński PH
Am J Otolaryngol; 2021; 42(2):102895. PubMed ID: 33429176
[TBL] [Abstract][Full Text] [Related]
5. Mastoid Obliteration with S53P4 Bioactive Glass Can Make Bonebridge Implantation Feasible: A Case Report.
Król B; Porowski M; Cywka KB; Skarżyńska MB; Skarżyński PH
Am J Case Rep; 2020 Nov; 21():e925914. PubMed ID: 33168798
[TBL] [Abstract][Full Text] [Related]
6. The Bonebridge BCI 602 Active Transcutaneous Bone Conduction Implant in Children: Objective and Subjective Benefits.
Cywka KB; Skarżyński H; Król B; Skarżyński PH
J Clin Med; 2021 Dec; 10(24):. PubMed ID: 34945210
[TBL] [Abstract][Full Text] [Related]
7. Tolerance and safety of 45S5 bioactive glass used in obliteration procedures during middle ear surgery: Preliminary results.
Al Tamami N; Bawazeer N; Fieux M; Zaouche S; Tringali S
Am J Otolaryngol; 2020; 41(6):102542. PubMed ID: 32620365
[TBL] [Abstract][Full Text] [Related]
8. Bioactive glass obliteration of the mastoid significantly improves surgical outcome in non-cholesteatomatous chronic otitis media patients.
Vos J; de Vey Mestdagh P; Colnot D; Borggreven P; Orelio C; Quak J
Eur Arch Otorhinolaryngol; 2017 Dec; 274(12):4121-4126. PubMed ID: 28956143
[TBL] [Abstract][Full Text] [Related]
9. Mastoid Obliteration Using S53P4 Bioactive Glass in Cholesteatoma Surgery: A 10-Year Single-Center Experience in 173 Adult Patients with Long-Term Magnetic Resonance Imaging Controlled Follow-up.
Kroon VJ; Mes SW; Borggreven PA; van de Langenberg R; Colnot DR; Quak JJ
Otol Neurotol; 2022 Dec; 43(10):1181-1188. PubMed ID: 36099589
[TBL] [Abstract][Full Text] [Related]
10. Audiological effectiveness of Bonebridge implantation for bilateral congenital malformation of the external and middle ear.
Ren R; Zhao S; Wang D; Li Y; Ma X; Li Y; Fu X; Chen P; Dou J
Eur Arch Otorhinolaryngol; 2019 Oct; 276(10):2755-2762. PubMed ID: 31267176
[TBL] [Abstract][Full Text] [Related]
11. Bonebridge
Carnevale C; Morales-Olavarría C; Til-Pérez G; Sarría-Echegaray P
Eur Arch Otorhinolaryngol; 2023 Apr; 280(4):1611-1619. PubMed ID: 36063211
[TBL] [Abstract][Full Text] [Related]
12. A middle ear implant with a titanium canal wall prosthesis for a case of an open mastoid cavity.
Deveze A; Rameh C; Sanjuan M; Lavieille JP; Magnan J
Auris Nasus Larynx; 2010 Oct; 37(5):631-5. PubMed ID: 20167445
[TBL] [Abstract][Full Text] [Related]
13. Mastoid obliteration with S53P4 bioactive glass in cholesteatoma surgery.
de Veij Mestdagh PD; Colnot DR; Borggreven PA; Orelio CC; Quak JJ
Acta Otolaryngol; 2017 Jul; 137(7):690-694. PubMed ID: 28125327
[TBL] [Abstract][Full Text] [Related]
14. Improvement of speech perception in quiet and in noise without decreasing localization abilities with the bone conduction device Bonebridge.
Weiss R; Leinung M; Baumann U; Weißgerber T; Rader T; Stöver T
Eur Arch Otorhinolaryngol; 2017 May; 274(5):2107-2115. PubMed ID: 28032241
[TBL] [Abstract][Full Text] [Related]
15. Bioglass reconstruction of posterior meatal wall after canal wall down mastoidectomy.
Sorour SS; Mohamed NN; Abdel Fattah MM; Elbary MEA; El-Anwar MW
Am J Otolaryngol; 2018; 39(3):282-285. PubMed ID: 29526381
[TBL] [Abstract][Full Text] [Related]
16. Hearing and hearing rehabilitation after obliteration of troublesome mastoid cavities.
Geerse S; Bost TJM; Allagul S; de Wolf MJF; Ebbens FA; van Spronsen E
Eur Arch Otorhinolaryngol; 2020 Dec; 277(12):3307-3313. PubMed ID: 32444965
[TBL] [Abstract][Full Text] [Related]
17. Audiological and clinical outcomes of a transcutaneous bone conduction hearing implant: Six-month results from a multicentre study.
den Besten CA; Monksfield P; Bosman A; Skarzynski PH; Green K; Runge C; Wigren S; Blechert JI; Flynn MC; Mylanus EAM; Hol MKS
Clin Otolaryngol; 2019 Mar; 44(2):144-157. PubMed ID: 30358920
[TBL] [Abstract][Full Text] [Related]
18. The Bonebridge implant in older children and adolescents with mixed or conductive hearing loss: Audiological outcomes.
Ratuszniak A; Skarzynski PH; Gos E; Skarzynski H
Int J Pediatr Otorhinolaryngol; 2019 Mar; 118():97-102. PubMed ID: 30599287
[TBL] [Abstract][Full Text] [Related]
19. Cholesteatoma surgery in the pediatric population: remaining challenges in the era of mastoid obliteration.
Kroon VJ; Mes SW; Borggreven PA; van de Langenberg R; Colnot DR; Quak JJ
Eur Arch Otorhinolaryngol; 2023 Apr; 280(4):1713-1722. PubMed ID: 36208330
[TBL] [Abstract][Full Text] [Related]
20. [Clinical application of retrosigmoid approach for BONEBRIDGE implantation after auricle reconstruction using expanded postauricular flap].
Wang DN; Wang BQ; Ren R; Chen PW; Liu YJ; Zhang QG; Zhao SQ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2023 Oct; 58(10):980-985. PubMed ID: 37840163
[No Abstract] [Full Text] [Related]
[Next] [New Search]
